DNA testing can detect early liver cancer – Mayo clinic study

Share This Post

Researchers at the Mayo Clinic in the United States reported at the 2018 Digestive Disease Week meeting that they have developed a DNA blood test that can correctly identify 95% of common liver cancer cases.

At present, ultrasound and alpha-fetoprotein detection are used clinically to detect liver cancer. This joint detection is not very sensitive to curable liver cancer. A recent study showed that this combined test can detect 63% of liver cancer cases. These tests are not very sensitive to curable liver cancer, and most people who need to be tested are not easy to obtain this kind of joint test or cannot be tested frequently enough to achieve effective detection.

The researchers used known liver cancer abnormal DNA markers. In the study of 244 patients, most of the blood samples from patients with primary liver cancer had abnormal DNA markers. The abnormal markers can accurately identify 95% of liver cancers. Patients, 93% of them are in a curable stage. These markers are not found in healthy people and patients with cirrhosis.

The researchers pointed out that the exciting thing is that DNA markers can detect more than 90% of patients with curable liver cancer, which is the main advantage of this test and the current test. The next step is to verify these marker blood tests in a larger sample cohort.

The researchers are devoted to exploring the biomarkers of 16 kinds of tumors, aiming to create two major tests, namely, the stool test is used for gastrointestinal tumors, and the blood test is used for other tumors including liver cancer and lung cancer.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy